Abbott India Ltd.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.30%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, prompting a downgrade in its Mojo Grade from Hold to Sell as of 12 May 2026.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent downgrade from Hold to Sell by MarketsMOJO on 12 May 2026, the stock exhibits a complex interplay of technical indicators that suggest cautious optimism amid prevailing market uncertainties.

Abbott India Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish signals on weekly charts, monthly indicators suggest caution, reflecting a complex technical landscape for investors to navigate.

Abbott India Ltd. witnessed a sharp gap down at the opening bell on 24 Jul 2026, reflecting heightened market apprehensions. The stock opened 4.3% lower, underperforming its sector and broader indices, signalling a weak start to the trading day amid ongoing downward momentum.

Abbott India Ltd. has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a 1.77% gain on 22 Jul 2026, the stock’s overall technical profile remains mixed, prompting a reassessment of its near-term outlook within the Pharmaceuticals & Biotechnology sector.

Abbott India Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 July 2026, providing investors with the latest insights into its performance and outlook.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from a Hold to a Sell rating by MarketsMOJO, the stock’s price action and technical indicators reveal a nuanced picture that investors must carefully analyse.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a more pronounced bearish trend. Recent technical indicators, including MACD, RSI, and moving averages, signal a complex landscape for investors as the stock price retreated by 1.79% on 9 July 2026, closing at ₹26,232.80.

Abbott India Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Abbott India Ltd. has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish trend, reflecting a complex interplay of technical indicators. Despite a strong intraday rally pushing the stock price to ₹26,851.80, the broader technical signals present a mixed picture, challenging investors to carefully weigh momentum against underlying market conditions.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen a marked shift in its valuation parameters, moving from an expensive to a very expensive rating. This change, coupled with a recent downgrade in its Mojo Grade from Hold to Sell, highlights growing concerns over the stock’s price attractiveness relative to its historical averages and peer group.

Abbott India Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The stock’s recent performance, combined with mixed technical signals, underscores a challenging outlook as it navigates downward pressure amid broader market dynamics.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a modest day gain of 0.32%, the stock’s technical parameters reveal a transition from bearish to mildly bearish trends, prompting a downgrade in its Mojo Grade from Hold to Sell as of 12 May 2026.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest day gain of 0.71%, the stock’s broader technical landscape suggests caution for investors as bearish signals intensify across multiple timeframes.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its valuation metrics shift markedly, moving from expensive to very expensive territory. Despite a modest day gain of 0.71%, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now stand well above peer averages, raising questions about price attractiveness amid mixed returns compared to the broader market.